Mutual of America Capital Management LLC Sells 1,943 Shares of Hologic, Inc. (NASDAQ:HOLX)

Mutual of America Capital Management LLC cut its stake in Hologic, Inc. (NASDAQ:HOLX) by 5.1% in the third quarter, Holdings Channel.com reports. The firm owned 36,354 shares of the medical equipment provider’s stock after selling 1,943 shares during the period. Mutual of America Capital Management LLC’s holdings in Hologic were worth $2,961,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. Wolff Wiese Magana LLC acquired a new stake in Hologic during the third quarter worth about $25,000. Innealta Capital LLC acquired a new stake in shares of Hologic during the 2nd quarter worth approximately $25,000. iA Global Asset Management Inc. acquired a new stake in shares of Hologic during the 1st quarter worth approximately $37,000. Sunbelt Securities Inc. bought a new stake in shares of Hologic during the second quarter valued at approximately $37,000. Finally, Cromwell Holdings LLC raised its stake in shares of Hologic by 330.2% in the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 416 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on HOLX. Evercore ISI lifted their price target on shares of Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research note on Tuesday, October 1st. Mizuho decreased their target price on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 5th. Leerink Partners dropped their price target on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Royal Bank of Canada lifted their price objective on Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a report on Tuesday, November 5th. Finally, StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a report on Thursday, November 14th. Four research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $89.91.

Hologic Stock Up 0.3 %

Shares of NASDAQ HOLX opened at $78.97 on Friday. Hologic, Inc. has a 12-month low of $67.59 and a 12-month high of $84.67. The firm’s 50-day simple moving average is $80.44 and its 200 day simple moving average is $78.34. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. The company has a market cap of $18.34 billion, a price-to-earnings ratio of 23.71, a price-to-earnings-growth ratio of 2.48 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, meeting analysts’ consensus estimates of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The firm had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. During the same period last year, the company earned $0.89 EPS. The business’s quarterly revenue was up 4.5% compared to the same quarter last year. On average, research analysts expect that Hologic, Inc. will post 4.27 earnings per share for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.